Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 64 articles:
HTML format

Single Articles

    February 2023
  1. WANG Y, Jain P, Locke FL, Maurer MJ, et al
    Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    J Clin Oncol. 2023 Feb 8:JCO2201797. doi: 10.1200/JCO.22.01797.
    PubMed     Abstract available

    January 2023
    Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.

  3. MCLAUGHLIN P, Grillo-Lopez AJ, Link BK, Levy R, et al
    Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
    J Clin Oncol. 2023;41:154-162.
    PubMed     Abstract available

  4. JCO Flashback: Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998).
    J Clin Oncol. 2023;41:153.

    December 2022
  5. THIEBLEMONT C, Phillips T, Ghesquieres H, Cheah CY, et al
    Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    J Clin Oncol. 2022 Dec 22:JCO2201725. doi: 10.1200/JCO.22.01725.
    PubMed     Abstract available

  6. LOWE EJ, Reilly AF, Lim MS, Gross TG, et al
    Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
    J Clin Oncol. 2022 Dec 19:JCO2200272. doi: 10.1200/JCO.22.00272.
    PubMed     Abstract available

  7. NASTOUPIL LJ, Bartlett NL
    Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2022 Dec 12:JCO2201848. doi: 10.1200/JCO.22.01848.
    PubMed     Abstract available

  8. BROCKELMANN PJ, Buhnen I, Meissner J, Trautmann-Grill K, et al
    Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
    J Clin Oncol. 2022 Dec 12:JCO2202355. doi: 10.1200/JCO.22.02355.
    PubMed     Abstract available

  9. RODDAY AM, Parsons SK, Upshaw JN, Friedberg JW, et al
    The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
    J Clin Oncol. 2022 Dec 10:JCO2202473. doi: 10.1200/JCO.22.02473.
    PubMed     Abstract available

  10. MERLI M, Rattotti S, Spina M, Re F, et al
    Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
    J Clin Oncol. 2022;40:4060-4070.
    PubMed     Abstract available

  11. HERMINE O, Jiang L, Walewski J, Bosly A, et al
    High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
    J Clin Oncol. 2022 Dec 5:JCO2201780. doi: 10.1200/JCO.22.01780.
    PubMed     Abstract available

    November 2022
  12. HILLMEN P, Eichhorst B, Brown JR, Lamanna N, et al
    Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200/JCO.22.00510.
    PubMed     Abstract available

    October 2022
  13. VIJENTHIRA A, Kuruvilla J, Crump M, Jain M, et al
    Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk
    J Clin Oncol. 2022 Oct 31:JCO2200478. doi: 10.1200/JCO.22.00478.
    PubMed     Abstract available

  14. LACASCE AS, Dockter T, Ruppert AS, Kostakoglu L, et al
    Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
    J Clin Oncol. 2022 Oct 21:JCO2200947. doi: 10.1200/JCO.22.00947.
    PubMed     Abstract available

  15. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
    Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
    PubMed     Abstract available

    September 2022
    Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation.
    J Clin Oncol. 2022 Sep 30:JCO2201337. doi: 10.1200/JCO.22.01337.
    PubMed     Abstract available

    Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide.
    J Clin Oncol. 2022 Sep 28:JCO2201661. doi: 10.1200/JCO.22.01661.
    PubMed     Abstract available

  18. KAHL BS
    Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?
    J Clin Oncol. 2022 Sep 1:JCO2201501. doi: 10.1200/JCO.22.01501.

    August 2022
  19. WESTIN J, Davis RE, Feng L, Hagemeister F, et al
    Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    J Clin Oncol. 2022 Aug 11:JCO2200597. doi: 10.1200/JCO.22.00597.
    PubMed     Abstract available

  20. DE VRIES S, Haaksma ML, Jozwiak K, Schaapveld M, et al
    Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma.
    J Clin Oncol. 2022 Aug 10:JCO2102613. doi: 10.1200/JCO.21.02613.
    PubMed     Abstract available

  21. MORSCHHAUSER F, Nastoupil L, Feugier P, Schiano de Colella JM, et al
    Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
    J Clin Oncol. 2022 Aug 10:JCO2200843. doi: 10.1200/JCO.22.00843.
    PubMed     Abstract available

    July 2022
  22. FORNECKER LM, Lazarovici J, Aurer I, Casasnovas RO, et al
    Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
    J Clin Oncol. 2022 Jul 22:JCO2101281. doi: 10.1200/JCO.21.01281.
    PubMed     Abstract available

  23. AMADOR C, Bouska A, Wright G, Weisenburger DD, et al
    Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102707. doi: 10.1200/JCO.21.02707.
    PubMed     Abstract available

  24. HOUILLIER C, Dureau S, Taillandier L, Houot R, et al
    Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
    J Clin Oncol. 2022 Jul 14:JCO2200491. doi: 10.1200/JCO.22.00491.
    PubMed     Abstract available

  25. WANG Y, Cao J, Gu W, Shi M, et al
    Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
    J Clin Oncol. 2022;40:2246-2256.
    PubMed     Abstract available

  26. RUTHERFORD SC, Yin J, Pederson L, Perez Burbano G, et al
    Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
    J Clin Oncol. 2022 Jul 5:JCO2102301. doi: 10.1200/JCO.21.02301.
    PubMed     Abstract available

    June 2022
  27. MARTIN P, Cohen JB, Wang M, Kumar A, et al
    Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
    J Clin Oncol. 2022 Jun 28:JCO2102698. doi: 10.1200/JCO.21.02698.
    PubMed     Abstract available

  28. WANG M, Munoz J, Goy A, Locke FL, et al
    Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    J Clin Oncol. 2022 Jun 4:JCO2102370. doi: 10.1200/JCO.21.02370.
    PubMed     Abstract available

    April 2022
  29. CHANG A, Akhtar A, Linderman SL, Lai L, et al
    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Apr 18:JCO2200088. doi: 10.1200/JCO.22.00088.
    PubMed     Abstract available

  30. LAKHOTIA R, Melani C, Roschewski M, Wilson WH, et al
    Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
    J Clin Oncol. 2022 Apr 4:JCO2102593. doi: 10.1200/JCO.21.02593.

    March 2022
  31. MIKHAEEL NG, Heymans MW, Eertink JJ, de Vet HCW, et al
    Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
    J Clin Oncol. 2022 Mar 31:JCO2102063. doi: 10.1200/JCO.21.02063.
    PubMed     Abstract available

  32. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed     Abstract available

  33. SHIBUSAWA M, Kusumi E, Murakami J, Tanimoto T, et al
    Response-Adapted Postinduction Strategy in Follicular Lymphoma.
    J Clin Oncol. 2022 Mar 11:JCO2102818. doi: 10.1200/JCO.21.02818.

  34. TEACHEY DT, Devidas M, Wood BL, Chen Z, et al
    Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200/JCO.21.02678.
    PubMed     Abstract available

  35. WADHWA D
    Turning Point.
    J Clin Oncol. 2022;40:801-802.

    February 2022
  36. ADVANI AS, Moseley A, O'Dwyer KM, Wood BL, et al
    SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200/JCO.21.01766.
    PubMed     Abstract available

  37. BUDDE LE, Assouline S, Sehn LH, Schuster SJ, et al
    Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    J Clin Oncol. 2022;40:481-491.
    PubMed     Abstract available

    January 2022
  38. CASULO C
    Response-Adapted Therapy in Follicular Lymphoma: At the Threshold of a Precision Approach.
    J Clin Oncol. 2022 Jan 25:JCO2102477. doi: 10.1200/JCO.21.02477.

  39. LAGERLOF I, Fohlin H, Enblad G, Glimelius B, et al
    Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.
    J Clin Oncol. 2022 Jan 25:JCO2102407. doi: 10.1200/JCO.21.02407.
    PubMed     Abstract available

  40. LOUARN N, Galicier L, Bertinchamp R, Lussato D, et al
    First Extensive Analysis of (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis.
    J Clin Oncol. 2022 Jan 24:JCO2101228. doi: 10.1200/JCO.21.01228.
    PubMed     Abstract available

  41. GINE E, de la Cruz F, Jimenez Ubieto A, Lopez Jimenez J, et al
    Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 14:JCO2102321. doi: 10.1200/JCO.21.02321.
    PubMed     Abstract available

  42. CASASNOVAS RO, Bouabdallah R, Brice P, Lazarovici J, et al
    Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
    J Clin Oncol. 2022 Jan 6:JCO2101777. doi: 10.1200/JCO.21.01777.
    PubMed     Abstract available

    December 2021
  43. SHOUVAL R, Alarcon Tomas A, Fein JA, Flynn JR, et al
    Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2021 Dec 3:JCO2102143. doi: 10.1200/JCO.21.02143.
    PubMed     Abstract available

    November 2021
    Moving Beyond One Size Fits All for T-Cell Lymphoma.
    J Clin Oncol. 2021 Nov 29:JCO2102463. doi: 10.1200/JCO.21.02463.

  45. BACHY E, Camus V, Thieblemont C, Sibon D, et al
    Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    J Clin Oncol. 2021 Nov 29:JCO2101815. doi: 10.1200/JCO.21.01815.
    PubMed     Abstract available

  46. JAIN P, Zhao S, Lee HJ, Hill HA, et al
    Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2021 Nov 19:JCO2101797. doi: 10.1200/JCO.21.01797.
    PubMed     Abstract available

    October 2021
  47. LUMINARI S, Manni M, Galimberti S, Versari A, et al
    Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
    J Clin Oncol. 2021 Oct 28:JCO2101234. doi: 10.1200/JCO.21.01234.
    PubMed     Abstract available

    September 2021
  48. BURKE GAA, Minard-Colin V, Auperin A, Alexander S, et al
    Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
    J Clin Oncol. 2021 Sep 27:JCO2100920. doi: 10.1200/JCO.21.00920.
    PubMed     Abstract available

  49. FRANK MJ, Hossain NM, Bukhari A, Dean E, et al
    Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
    J Clin Oncol. 2021;39:3034-3043.
    PubMed     Abstract available

    August 2021
    Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress.
    J Clin Oncol. 2021 Aug 24:JCO2101552. doi: 10.1200/JCO.21.01552.
    PubMed     Abstract available

  51. CUTTER DJ, Ramroth J, Diez P, Buckle A, et al
    Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2021 Aug 13:JCO2100408. doi: 10.1200/JCO.21.00408.
    PubMed     Abstract available

    June 2021
  52. OVLISEN AK, Jakobsen LH, Eloranta S, Kragholm KH, et al
    Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study.
    J Clin Oncol. 2021 Jun 25:JCO2100357. doi: 10.1200/JCO.21.00357.
    PubMed     Abstract available

  53. MOSKOWITZ AJ, Shah G, Schoder H, Ganesan N, et al
    Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jun 25:JCO2101056. doi: 10.1200/JCO.21.01056.
    PubMed     Abstract available

  54. DEMEESTERE I, Racape J, Dechene J, Dupuis J, et al
    Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).
    J Clin Oncol. 2021 Jun 22:JCO2100068. doi: 10.1200/JCO.21.00068.
    PubMed     Abstract available

    May 2021
  55. SMITH SD, Gopal AK
    Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL.
    J Clin Oncol. 2021;39:1671-1673.

    April 2021
  56. ALIG S, Macaulay CW, Kurtz DM, Duhrsen U, et al
    Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2002573. doi: 10.1200/JCO.20.02573.
    PubMed     Abstract available

  57. KUMAR A, Casulo C, Advani RH, Budde E, et al
    Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2100108. doi: 10.1200/JCO.21.00108.
    PubMed     Abstract available

  58. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    PubMed     Abstract available

    Precision Medicine in DLBCL: Are We There Yet?
    J Clin Oncol. 2021;39:1314-1316.

  60. SMITH SM
    Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance.
    J Clin Oncol. 2021;39:1193-1195.

  61. METZGER ML, Link MP, Billett AL, Flerlage J, et al
    Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    J Clin Oncol. 2021 Apr 7:JCO2003286. doi: 10.1200/JCO.20.03286.
    PubMed     Abstract available

  62. RAMER SJ
    This Is Not Happening.
    J Clin Oncol. 2021;39:1162-1164.

    February 2021
  63. HESLOP HE, Sharma S, Rooney CM
    Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
    J Clin Oncol. 2021;39:514-524.

  64. AOKI T, Savage KJ, Steidl C
    Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers.
    J Clin Oncol. 2021;39:346-360.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.